| Assessment Status | Rapid Review Complete |
| HTA ID | 25023 |
| Drug | Upadacitinib |
| Brand | Rinvoq® |
| Indication | Upadacitinib is indicated for the treatment of giant cell arteritis in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 25/03/2025 |
| Rapid review completed | 17/04/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of upadacitinib compared with the current standard of care. |